ACHC granted its Specialty Pharmacy accreditation to the Plymouth, Minn.-based company’s central specialty pharmacy, as well as its Specialty at Retail accreditation to the chain’s 100 community pharmacy locations.
With this approval — which saw the drug given Priority Review, Breakthrough Therapy Designation and Orphan Drug Designation by the FDA — Rituxan becomes the first biologic therapy for the disease.
The Memphis-based company unloaded the business unit, EntrustRx, to a CVS Health subsidiary for a $40 million aggregate consideration, plus the value of its inventory.
The Food and Drug Administration sent Amgen a complete response letter for its Biologics License application for potential Herceptin biosimilar ABP 90.
Fulphila is the first U.S. biosimilar of the drug from Amgen and is indicated to reduce the duration of febrile neutropenia in patients treated with chemotherapy in certain types of cancer.
McKesson announced on Friday that it has completed its previously announced acquisition of Medical Specialties Distributors, a distributor of infusion and medical-surgical supplies as well as biomedical services to alternate site and home health providers.
The Phair Pricing Act of 2018 looks to make more transparent the prices that pharmacy benefit managers and prescription drug plan sponsors negotiate with pharmacies.